This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

China blocks completed vertical pharma deal in rare post merger move

By MLex Staff ( July 24, 2025, 07:10 GMT | Insight) -- China's antitrust regulator has ordered Wuhan Yongtong Pharmaceutical to unwind its 2018 acquisition of Shandong Beida Gaoke Huatai Pharmaceutical, marking an unusual retrospective intervention against a completed merger. The State Administration for Market Regulation said the merger eliminated competition in the Chinese market for papaverine hydrochloride injections, a critical vasodilator used in microsurgery for reattaching severed fingers. China's antitrust regulator has ordered Wuhan Yongtong Pharmaceutical to unwind its 2018 acquisition of Shandong Beida Gaoke Huatai Pharmaceutical, marking an unusual retrospective intervention against a completed merger....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login